FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318269855> ?p ?o ?g. }

• W4318269855 endingPage "126" @default.
• W4318269855 startingPage "125" @default.
• W4318269855 abstract "Coronary artery disease remains the leading cause of death worldwide, despite advances in both pharmacological and interventional management. Inflammation is involved in atherosclerosis, both early in the formation and later triggering the rupture of a vulnerable plaque. Recently, cytokine-targeted treatment approaches have emerged as promising in the management of atherosclerotic disease. Inhibition of interleukin-1β by canakinumab reduced the rate of cardiovascular events by 15% in the CANTOS study (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) [ [1] Ridker P.M. Everett B.M. Thuren T. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 2017; 377: 1119-1131https://doi.org/10.1056/NEJMoa1707914 Crossref PubMed Scopus (5125) Google Scholar ]. However, canakinumab's use may lead to significant side effects (increased risk of fatal infections, leukopenia, thrombocytopenia), while its high cost prevents from a widespread clinical translation in the setting of secondary prevention. In addition, the administration of Tocilizumab, a humanized monoclonal antibody against the IL-6 receptor, after myocardial infarction, reduced myocardial/reperfusion injuries [ [2] Broch K. Anstensrud A.K. Woxholt S. et al. Randomized trial of Interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 2021; 77: 1845-1855https://doi.org/10.1016/j.jacc.2021.02.049 Crossref PubMed Scopus (115) Google Scholar ]. Furthermore, colchicine, a low-cost and well-known anti-inflammatory agent widely used in pericarditis, gout, and familial Mediterranean fever, has been shown to inhibits the pathways involving IL-1β, IL-6, and IL-18. Several large international clinical studies have shown that Colchicine is associated with a significantly lower non-fatal cardiovascular events in patients with coronary disease compared to placebo group. Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trialInternational Journal of CardiologyVol. 372PreviewLow-dose colchicine significantly reduces the risk of cardiovascular events in patients with chronic coronary disease. An increase of non-cardiovascular death raised concerns about its safety. This study reports cause-specific mortality and baseline predictors of mortality in the Low-Dose Colchicine 2 (LoDoCo2) trial. Full-Text PDF Open Access" @default.
• W4318269855 created "2023-01-28" @default.
• W4318269855 creator A5035015657 @default.
• W4318269855 creator A5047333951 @default.
• W4318269855 creator A5062580609 @default.
• W4318269855 date "2023-04-01" @default.
• W4318269855 modified "2023-09-30" @default.
• W4318269855 title "Could colchicine reduce cardiovascular events in coronary artery disease without increasing all-cause mortality: Avoid optical illusions!" @default.
• W4318269855 cites W2043808606 @default.
• W4318269855 cites W2264767503 @default.
• W4318269855 cites W2748400555 @default.
• W4318269855 cites W2754725453 @default.
• W4318269855 cites W2986700515 @default.
• W4318269855 cites W3081761942 @default.
• W4318269855 cites W3082165044 @default.
• W4318269855 cites W3108232419 @default.
• W4318269855 cites W3153495812 @default.
• W4318269855 cites W4311764551 @default.
• W4318269855 doi "https://doi.org/10.1016/j.ijcard.2023.01.064" @default.
• W4318269855 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36716969" @default.
• W4318269855 hasPublicationYear "2023" @default.
• W4318269855 type Work @default.
• W4318269855 citedByCount "0" @default.
• W4318269855 crossrefType "journal-article" @default.
• W4318269855 hasAuthorship W4318269855A5035015657 @default.
• W4318269855 hasAuthorship W4318269855A5047333951 @default.
• W4318269855 hasAuthorship W4318269855A5062580609 @default.
• W4318269855 hasBestOaLocation W43182698552 @default.
• W4318269855 hasConcept C126322002 @default.
• W4318269855 hasConcept C164705383 @default.
• W4318269855 hasConcept C2778213512 @default.
• W4318269855 hasConcept C2779134260 @default.
• W4318269855 hasConcept C2779676291 @default.
• W4318269855 hasConcept C2779725882 @default.
• W4318269855 hasConcept C2781228260 @default.
• W4318269855 hasConcept C500558357 @default.
• W4318269855 hasConcept C71924100 @default.
• W4318269855 hasConceptScore W4318269855C126322002 @default.
• W4318269855 hasConceptScore W4318269855C164705383 @default.
• W4318269855 hasConceptScore W4318269855C2778213512 @default.
• W4318269855 hasConceptScore W4318269855C2779134260 @default.
• W4318269855 hasConceptScore W4318269855C2779676291 @default.
• W4318269855 hasConceptScore W4318269855C2779725882 @default.
• W4318269855 hasConceptScore W4318269855C2781228260 @default.
• W4318269855 hasConceptScore W4318269855C500558357 @default.
• W4318269855 hasConceptScore W4318269855C71924100 @default.
• W4318269855 hasLocation W43182698551 @default.
• W4318269855 hasLocation W43182698552 @default.
• W4318269855 hasLocation W43182698553 @default.
• W4318269855 hasLocation W43182698554 @default.
• W4318269855 hasOpenAccess W4318269855 @default.
• W4318269855 hasPrimaryLocation W43182698551 @default.
• W4318269855 hasRelatedWork W2102497552 @default.
• W4318269855 hasRelatedWork W2131694614 @default.
• W4318269855 hasRelatedWork W2161858472 @default.
• W4318269855 hasRelatedWork W2417414779 @default.
• W4318269855 hasRelatedWork W2790353319 @default.
• W4318269855 hasRelatedWork W3008408616 @default.
• W4318269855 hasRelatedWork W3181019448 @default.
• W4318269855 hasRelatedWork W3190582800 @default.
• W4318269855 hasRelatedWork W4313525342 @default.
• W4318269855 hasRelatedWork W4318269855 @default.
• W4318269855 hasVolume "376" @default.
• W4318269855 isParatext "false" @default.
• W4318269855 isRetracted "false" @default.
• W4318269855 workType "article" @default.